Nano-X Imaging Balances Growth Hopes With Deepening Losses

Nano-X Imaging Ltd. ((NNOX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Nano-X Imaging’s latest earnings call struck a cautious balance between operational momentum and financial strain. Management highlighted expanding commercial agreements, regulatory wins and a growing technology platform, yet also confronted widening losses, weak hardware economics and uncertainty around when today’s pipeline will convert into meaningful, sustainable revenue.

Expanding Distribution Deals and Hardware Deployment Pipeline

Nano-X underscored a major framework deal with Howard Technology Solutions that targets deployment of 300 Nanox.ARC systems over three years, including 60 units in the first year. Across all partners, management pointed to agreements covering roughly 360 systems over two to three years and a broader global opportunity of about 400 systems, with 38 units in various deployment stages and around 15 due for installation in the coming months.

Teleradiology Drives Modest Revenue Growth

For Q4 2025, revenue rose 23% year over year to $3.7 million, led by the teleradiology business which generated $3.1 million versus $2.8 million a year ago. Non‑GAAP teleradiology gross profit reached $1.5 million, lifting the segment’s margin to roughly 48% as Nano-X benefited from strong customer retention, higher pricing and increased reading volumes.

2026 Revenue Ramp Hinges on Channel Activation

Management reiterated its full‑year 2026 revenue target of $35 million, with most of the acceleration expected in the back half of the year. The company expects onboarding and activation of recently signed channel and distribution agreements, including the Howard framework and other contracts, to drive this ramp, but acknowledged that timing of system go‑lives remains a key variable.

Acquisition Adds Health IT Scale and AI Validation

Nano-X closed the acquisition of VasoHealthcare IT in November 2025, rebranding it as Nanox Health IT and contributing about $0.4 million of revenue in the quarter. Management said the acquired unit should add revenue from day one, deepen integration of Nanox.AI into clinical workflows and enhance lead generation, supported by clinical work such as a Cedars‑Sinai study on roughly 600 retrospective cases.

Regulatory Milestones and Industry Recognition Build Credibility

On the regulatory front, Nano-X secured clearance for its TAP2D 2D output in the U.S. and obtained an updated AMAR approval in Israel that removes prior adjunctive-use constraints. The company is preparing a CE Mark submission for 2026 and highlighted recent product design and conference awards as evidence of improving perception among clinicians and industry stakeholders.

Liquidity Cushion Strengthened by Equity Raise

The balance sheet showed cash, cash equivalents and marketable securities of around $60 million at year‑end, up from $55.5 million at the prior quarter’s close. Nano-X raised roughly $15.5 million in net proceeds during Q4 by selling approximately 4.2 million shares, providing additional runway to fund restructuring and commercialization efforts.

R&D Advances in Field-Emission and Multisource X-ray

Nano-X reported continued progress on its next-generation field‑emission X‑ray sources, including improved emitter designs plus micro‑focus and multi‑zone work. The Nanox.MDX multisource tube program is advancing through multiple pilot projects, including a purchase order from a leading semiconductor equipment maker and ongoing prototype collaboration with Oak Ridge.

Large GAAP Loss Dominated by Asset Impairment

The company posted a GAAP net loss of $33.4 million for Q4 2025, more than double the $14.1 million loss in the prior year period. The swing was driven mainly by a noncash $17.5 million impairment of long‑lived assets tied to the restructuring of its South Korea fabrication facility.

Manufacturing Reset Aims to Cut Costs Over Time

Nano-X is closing its chip manufacturing line in South Korea and shifting to outsourced production with partners such as CSEM, reducing its property and equipment balance to $29.7 million from $45.4 million. Management expects the move to lower operating expenses and cash burn over time, while cautioning that some restructuring-related cash outflows may still arise in 2026.

Negative Hardware Economics Pressure Gross Margin

Non‑GAAP gross loss widened to $1.2 million, translating into a roughly 32% negative margin compared with about 9% previously. System sales were particularly weak, with just $49,000 of revenue generating a $2.6 million GAAP and non‑GAAP gross loss, underscoring the heavy cost burden of early Nanox.ARC deployments.

Higher Operating Spend Fuels Wider Non-GAAP Loss

Sales and marketing expenses more than doubled to $2.0 million, driven by new hires and increased presence at industry events such as RSNA. Non‑GAAP net loss attributable to ordinary shares widened to $11.2 million from $10.0 million, while additional other expenses of $1.4 million, largely tied to a shareholder settlement, added to the overall cost base.

Early-Stage Deployments and Revenue Timing Risks

Management stressed that many installed or in‑process systems are still early in their lifecycle and some are not yet generating revenue. The pace of installations and activations depends on local import permits, site construction and regulatory reviews, creating meaningful uncertainty around when today’s pipeline will translate into recurring income.

AI and Software Still in Nascent Monetization Phase

AI and software revenue improved to $0.5 million from $0.1 million, reflecting early commercial traction for Nanox.AI. However, the segment posted a GAAP gross loss of $1.9 million and only a modest non‑GAAP gross profit, indicating that scale and better cost leverage will be needed before AI and software materially support margins.

Guidance Centers on 2026 Inflection and Restructuring Benefits

Guidance reaffirmed a $35 million revenue goal for fiscal 2026, with management signaling that the majority of growth should come in the second half as roughly 38 systems in the pipeline move toward installation and about 15 are set to be installed soon. The company framed its $60 million cash balance, equity raise and Korea fab restructuring as key levers to support this transition and ultimately curb cash use.

Nano-X’s earnings call painted a story of promising commercial and technological advances that are not yet reflected in the bottom line. Investors will be watching whether the large distribution pipeline, AI and IT initiatives and manufacturing reset can overcome current losses and negative hardware economics to deliver the targeted 2026 revenue inflection.